Payment overview · 2025
General Payments
$95.51
4 reported records · 4 companies
Healthcare provider profile · identity verified
Joseph Amato, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1417986050
Verified facts
What the public records show
CMS Open Payments records show Joseph Amato, M.D. received $95.51 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.44 | 36.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $33.69 | 35.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.79 | 14.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $13.59 | 14.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $95.51 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $34.44 | 1 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $33.69 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 549 | 168 |
| Levothyroxine Sodium | Levothyroxine Sodium | 335 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 293 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 87 |
| Lisinopril | Lisinopril | 281 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 83 |
| Metformin Hcl | Metformin Hcl | 236 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 62 |
| Omeprazole | Omeprazole | 189 | 64 |
| Gabapentin | Gabapentin | 183 | 60 |
| Ozempic | Semaglutide | 173 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 45 |
| Meloxicam | Meloxicam | 138 | 54 |
| Montelukast Sodium | Montelukast Sodium | 136 | 42 |
| Losartan Potassium | Losartan Potassium | 135 | 41 |
| Famotidine | Famotidine | 127 | 41 |
| Potassium Chloride | Potassium Chloride | 120 | 42 |
| Jardiance | Empagliflozin | 114 | 25 |
| Trazodone Hcl | Trazodone Hcl | 114 | 39 |
| Furosemide | Furosemide | 111 | 39 |
| Carvedilol | Carvedilol | 107 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 25 |
| Farxiga | Dapagliflozin Propanediol | 95 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 26 |
| Fenofibrate | Fenofibrate | 86 | 22 |
| Sertraline Hcl | Sertraline Hcl | 85 | 29 |
| Telmisartan | Telmisartan | 84 | 26 |
| Ibandronate Sodium | Ibandronate Sodium | 82 | 33 |
| Ezetimibe | Ezetimibe | 81 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 28 |
| Mounjaro | Tirzepatide | 76 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 24 |
| Mirtazapine | Mirtazapine | 67 | 21 |
| Allopurinol | Allopurinol | 65 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 18 |
| Prednisone | Prednisone | 62 | 52 |
| Simvastatin | Simvastatin | 61 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 24 |
| Pregabalin | Pregabalin | 56 | 22 |
| Azelastine Hcl | Azelastine Hcl | 46 | 16 |
| Enalapril Maleate | Enalapril Maleate | 46 | 12 |
| Buspirone Hcl | Buspirone Hcl | 41 | 13 |
| Glimepiride | Glimepiride | 39 | 17 |
| Ondansetron Odt | Ondansetron | 39 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 11 |
| Cefdinir | Cefdinir | 33 | 33 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 12 |
| Atenolol | Atenolol | 29 | 14 |
| Eliquis | Apixaban | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Finasteride | Finasteride | 27 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Invokana | Canagliflozin | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | 12 |
| Linzess | Linaclotide | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Indapamide | Indapamide | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Repatha Pushtronex | Evolocumab | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $95.51 · 4 records | AstraZeneca Pharmaceuticals LP | Cologuard Collection Kit, FARXIGA, MCOT, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error